CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...